Trillium Therapeutics is in the healthcare sector and is part of the biotechnology industry. The company CEO is Niclas Stiernholm. Trillium Therapeutics Inc is an immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc and CD200 monoclonal antibody targets immuno regulatory pathways that tumor cells exploit to evade the host immune system.

Previous Intraday Performance:

The TRIL shares had a previous change of -4.96% which opened at 0.41 and closed at 0.39. It moved to an intraday high of 0.41 and a low of 0.38.

SeekingAlpha:  Aduro down 42% on underwhelming data on STING candidate

Historical Performance:

Over the last five trading days, TRIL shares returned -3.73% and in the past 30 trading days it returned -32.28%. Over three months, it changed -42.26%. In one year it has changed -93.79% and within that year its 52 week high was 7.00 and its 52 week low was 0.35. TRIL stock is 10.98% above its 52 week low.

Our calculations result in a 200 day moving average of 2.22 and a 50 day moving average of 0.55. Right now, TRIL stock is trading -82.63% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Aduro down 42% on underwhelming data on STING candidate


The company has a market cap of $10.1m with 26.3m shares outstanding and a float of 26.3m shares. Trading volume was 390,875 shares and has experienced an average volume of 947,152 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


Based on 2 analyst estimates, the consensus EPS for the next quarter is -0.42.

Below was the last reported quarterly diluted earnings per share:

1stQtr 2019Reported 05-13-2019: -0.46
4thQtr 2018Reported 03-11-2019: -0.42
3rdQtr 2018Reported 11-14-2018: -0.70
2ndQtr 2018Reported 08-08-2018: -0.70
1stQtr 2018Reported 05-11-2018: -0.50

The long-term trend of the EPS is a vital number as it helps understand the future potential of Trillium Therapeutics.

Indicators Also to Watch:

Based on the latest filings, there is 22.70% of institutional ownership.

The beta was calculated to be 2.49.

SeekingAlpha:  Textainer Group Holdings Limited 2019 Q1 – Results – Earnings Call Slides

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -60.08% and price-to-book is 3.72.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here